Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGILITY: Entospletinib in NPM1-mutated AML
NCT05020665Phase 3Terminated
- Sponsor
- Kronos Bio, Inc.
- Start
- Nov 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of entospletinib in acute myeloid leukemia (AML), sponsored by Kronos Bio, Inc.. Started Nov 2021; status: terminated.
02
Drugs
entospletinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05020665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05020665.